Analysis of Prior Aspirin Treatment on in-Hospital Outcome of Geriatric COVID-19 Infected Patients

被引:0
作者
Zekri-Nechar, Khaoula [1 ]
Barberan, Jose [2 ]
Zamorano-Leon, Jose J. [3 ]
Durban, Maria [4 ]
Andres-Castillo, Alcira [1 ]
Navarro-Cuellar, Carlos [5 ]
Lopez-Farre, Antonio [1 ]
Lopez-de-Andres, Ana [3 ]
Jimenez-Garcia, Rodrigo [3 ]
Martinez-Martinez, Carlos H. [1 ]
机构
[1] Univ Complutense Madrid, Sch Med, Med Dept, Madrid 28040, Spain
[2] HM Hosp, Internal Med Dept, Madrid 28250, Spain
[3] Univ Complutense Madrid, Sch Med, Publ Hlth & Maternal & Child Hlth Dept, IdISSC, Madrid 28040, Spain
[4] Univ Carlos III, Stat Dept, Madrid 28903, Spain
[5] Hosp Gen Univ Gregorio Maranon, Maxillofacial Surg Dept, Madrid 28007, Spain
来源
MEDICINA-LITHUANIA | 2022年 / 58卷 / 11期
关键词
aspirin; COVID-19; elderly population; low molecular weight heparin; pulmonary thromboembolism; mortality; hospital stay; MOLECULAR-WEIGHT HEPARIN; LOW-DOSE ASPIRIN; CORONAVIRUS DISEASE 2019; VENOUS THROMBOEMBOLISM; MORTALITY; PREVENTION; RISK;
D O I
10.3390/medicina58111649
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives: Aspirin (ASA) is a commonly used antithrombotic drug that has been demonstrated to reduce venous thromboembolism. The aim was to analyze if geriatric COVID-19 patients undergoing a 100 mg/day Aspirin (ASA) treatment prior to hospitalization differ in hospital outcome compared to patients without previous ASA therapy. Materials and Methods: An observational retrospective study was carried out using an anonymized database including geriatric COVID-19 patients (March to April 2020) admitted to Madrid Hospitals Group. A group of COVID-19 patients were treated with low ASA (100 mg/day) prior to COVID-19 infection. Results: Geriatric ASA-treated patients were older (mean age over 70 years; n = 41), had higher frequency of hypertension and hyperlipidemia, and upon admission had higher D-dimer levels than non-ASA-treated patients (mean age over 73 years; n = 160). However, patients under ASA treatment did not show more frequent pulmonary thromboembolism (PE) than non-ASA-treated patients. ASA-treated geriatric COVID-19-infected patients in-hospital < 30 days all-cause mortality was more frequent than in non-ASA-treated COVID-19 patients. In ASA-treated COVID-19-infected geriatric patients, anticoagulant therapy with low molecular weight heparin (LMWH) significantly reduced need of ICU care, but tended to increase in-hospital < 30 days all-cause mortality. Conclusions: Prior treatment with a low dose of ASA in COVID-19-infected geriatric patients increased frequency of in-hospital < 30 days all-cause mortality, although it seemed to not increase PE frequency despite D-dimer levels upon admission being higher than in non-ASA users. In ASA-treated geriatric COVID-19-infected patients, addition of LMWH therapy reduced frequency of ICU care, but tended to increase in-hospital < 30 days all-cause mortality.
引用
收藏
页数:9
相关论文
共 34 条
  • [1] Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major Referral Center in Iran
    Alamdari, Nasser Malekpour
    Afaghi, Siamak
    Rahimi, Fatemeh Sadat
    Tarki, Farzad Esmaeili
    Tavana, Sasan
    Zali, Alireza
    Fathi, Mohammad
    Besharat, Sara
    Bagheri, Leyla
    Pourmotahari, Fatemeh
    Irvani, Seyed Sina Naghibi
    Dabbagh, Ali
    Mousavi, Seyed Ali
    [J]. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2020, 252 (01) : 73 - 84
  • [2] Platelets and infection - an emerging role of platelets in viral infection
    Assinger, Alice
    [J]. FRONTIERS IN IMMUNOLOGY, 2014, 5
  • [3] Aspirin for Preventing the Recurrence of Venous Thromboembolism
    Becattini, Cecilia
    Agnelli, Giancarlo
    Schenone, Alessandro
    Eichinger, Sabine
    Bucherini, Eugenio
    Silingardi, Mauro
    Bianchi, Marina
    Moia, Marco
    Ageno, Walter
    Vandelli, Maria Rita
    Grandone, Elvira
    Prandoni, Paolo
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (21) : 1959 - 1967
  • [4] Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain
    Berenguer, Juan
    Ryan, Pablo
    Rodriguez-Bano, Jesus
    Jarrin, Inmaculada
    Carratala, Jordi
    Pachon, Jeronimo
    Yllescas, Maria
    Arriba, Jose Ramon
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2020, 26 (11) : 1525 - 1536
  • [5] Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism
    Brighton, Timothy A.
    Eikelboom, John W.
    Mann, Kristy
    Biostat, M.
    Mister, Rebecca
    Gallus, Alexander
    Ockelford, Paul
    Gibbs, Harry
    Hague, Wendy
    Xavier, Denis
    Diaz, Rafael
    Kirby, Adrienne
    Simes, John
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (21) : 1979 - 1987
  • [6] Therapeutic dosing of low-molecular-weight heparin may decrease mortality in patients with severe COVID-19 infection
    Canoglu, Kadir
    Saylan, Bengu
    [J]. ANNALS OF SAUDI MEDICINE, 2020, 40 (06) : 462 - 468
  • [7] Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
    Chen, Nanshan
    Zhou, Min
    Dong, Xuan
    Qu, Jieming
    Gong, Fengyun
    Han, Yang
    Qiu, Yang
    Wang, Jingli
    Liu, Ying
    Wei, Yuan
    Xia, Jia'an
    Yu, Ting
    Zhang, Xinxin
    Zhang, Li
    [J]. LANCET, 2020, 395 (10223) : 507 - 513
  • [8] Choi Geun Joo, 2020, J Lipid Atheroscler, V9, P435, DOI 10.12997/jla.2020.9.3.435
  • [9] Clausen TM, 2020, CELL, V183, P1043, DOI [10.1016/j.cell.2020.09.033, 10.1101/2020.07.14.201616]
  • [10] Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events
    Eikelboom, JW
    Hirsh, J
    Weitz, JI
    Johnston, M
    Yi, Q
    Yusuf, S
    [J]. CIRCULATION, 2002, 105 (14) : 1650 - 1655